Andrew Gengos
CIK 1563623 · Chief Financial Officer · last filed 2026-07-17
Andrew Gengos is a Chief Financial Officer who has filed 29 SEC Form 4 insider transactions across 8 companies since 2012. The most recent filing, for IMRX, was dated Jul 17, 2026. Across all open-market trades the lifetime net is +$389.1K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $101.1K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$101.1K
8
29
$389.1K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMRX | Chief Financial Officer | — | $5.21 | — | $0 | 1 | 2026-07-17 |
| TTRX | Director | 10,000 | $10.11 | $101.1K | $0 | 2 | 2026-06-08 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Chief Financial Officer | 0 | $52.95 | $0 | $96.4K | 5 | 2026-05-05 |
| LeonaBio, Inc. (ATHA) Delisted | CFO and Chief Business Officer | 97,532 | $6.92 | $674.9K | $235.3K | 7 | 2024-09-05 |
| Cyteir Therapeutics, Inc. (CYT) Delisted | Chief Business Officer | — | $3.02 | — | $0 | 1 | 2022-02-24 |
| SYNLOGIC, INC. (SYBX) Delisted | Chief Operating Officer | — | $0.69 | — | $0 | 2 | 2018-03-15 |
| ImmunoCellular Therapeutics, Ltd. (IMUC.WS) Delisted | Director | 6,424 | — | — | $0 | 1 | 2017-02-13 |
| ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted | President and CEO | 971 | — | — | $57.5K | 10 | 2016-03-15 |
Recent Filings
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-17 | IMRX | Grant (A) | — | $0 | EDGAR |
| 2026-06-08 | TTRX | Grant (A) | — | $0 | EDGAR |
| 2026-05-05 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Mixed | −109,253 | -$5.79M | EDGAR |
| 2026-01-16 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | +68,750 | $0 | EDGAR |
| 2025-10-10 | TTRX | Grant (A) | +10,000 | $0 | EDGAR |
| 2025-06-30 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Buy (P) | +10,000 | $39.3K | EDGAR |
| 2025-06-16 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Buy (P) | +15,000 | $57.1K | EDGAR |
| 2025-02-25 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-09-05 | LeonaBio, Inc. (ATHA) Delisted | Mixed | +13,728 | $12.7K | EDGAR |
| 2024-02-16 | LeonaBio, Inc. (ATHA) Delisted | Mixed | +3,792 | -$3.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.